P23. Efficient ex vivo lysis of acute myeloid leukaemic (AML) cells mediated by triplebodies with dual-targeting capability in conjunction with natural killer cells as effectors

Overview of attention for article published in Journal for Immunotherapy of Cancer, March 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

patent: 2 patents

Summary Patents

So far, Altmetric has seen 2 patents that reference this research output.

A CD33-, CD16- AND CD123-SPECIFIC SINGLE CHAIN TRIPLEBODY

Application WO-2018100139-A1

World Intellectual Property Organisation (WIPO)

A CD33-, CD16- AND CD123-SPECIFIC SINGLE CHAIN TRIPLEBODY

Application EP-3330289-A1

European Patent Office

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.